Creating a database for obesity patients
Official title: Obesity Queue Database
Run by RenJi Hospital · NCT06391320 · Data updated 2026-11-12
This study is creating a database of information from adults with simple obesity to help researchers better understand and address obesity-related health issues in the future.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | September 1, 2023 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | April 30, 2024 |
| Trial ID | NCT06391320 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-75 with simple obesity, defined by specific BMI and waist measurements.
✕Probably not a fit
Patients with complex obesity or those outside the specified age range may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a specialized database for patients with simple obesity to facilitate high-quality real-world clinical research. By collecting and organizing data from participants, the study seeks to create a comprehensive cohort that can support future investigations into obesity-related health issues. The methodology involves gathering clinical information from eligible patients aged 18-75 who meet specific obesity criteria, ensuring a focused approach to understanding this condition.
Why it matters
Potential benefit: If successful, this database could enhance the understanding of obesity and improve treatment strategies for patients.
How similar studies have gone: While similar cohort studies have been conducted, the establishment of a dedicated obesity database represents a focused effort that may yield novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-75 years with simple obesity. Simple obesity diagnosis criteria: meet one of the following conditions 1. BMI≥25 kg/m2 2. Waist circumference for male/female ≥90/80 cm 3. Waist-to-hip ratio: 0.9 (male); 0.85 (female) Exclusion Criteria: * Patients aged 18-75 years with simple obesity. Simple obesity diagnosis criteria: meet one of the following conditions 1. BMI≥25 kg/m2 2. Waist circumference for male/female ≥90/80 cm 3. Waist-to-hip ratio: 0.9 (male); 0.85 (female)
Where it's running
-
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jing Ma
- Email: cherry1996@live.cn
- Phone: +86 158 0098 3436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.